21 May 2013
Keywords: agouron, viracept, oked, europe, pharmaceuticals, received, clearance
Article | 29 January 1998
Agouron Pharmaceuticals has received clearance from the EuropeanCommission to market its protease inhibitor Viracept (nelfinavir mesylate) for the treatment of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.